IMG-7289 in Patients With Essential Thrombocythemia

• Status: Recruiting
• Trial end date: 2022-06-01
• Target enrollment: 0
• Participant gender: All

Summary

This is a Phase 2b open label study of an orally administered LSD1 inhibitor, IMG-7289, in patients with essential thrombocythemia.

This study investigates the following:

• The safety and tolerability of IMG-7289

• The pharmacodynamic effect of IMG-7289

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Imago BioSciences,Inc.

Criteria

Inclusion Criteria:

• Diagnosis of Essential Thrombocythemia per World Health Organization (WHO) diagnostic criteria for myeloproliferative neoplasms.

• Requires treatment in order to lower platelet count based on patient age over 60 or history of thrombosis.

• Have failed at least one standard therapy

• Must have discontinued ET therapy at least 1 week (4 weeks for interferon) prior to study drug initiation.

Exclusion Criteria:

• Has undergone major surgery ≤4 weeks prior to starting study drug or has not recovered from side effects of such surgery.

• Unresolved treatment related toxicities from prior therapies (unless resolved to ≤ Grade 1).

• Uncontrolled active infection.

• Current use of prohibited medications

• Known HIV infection or active Hepatitis B or Hepatitis C virus infection

• Other hematologic/biochemistry requirements, as per protocol

• Use of investigational agent within last 14 days

• Pregnant or lactating females